Abstract
The main goal of this project is to advance for an efficient therapy for Duchenne Muscular Dystrophy (DMD) based on a novel therapeutic approach. DMD is the most common and severe muscular dystrophy, affecting 1 in 3.500 to 5000 newborn male children. DMD is caused by the absence of dystrophin, an intracellular membrane-associated protein responsible for damping the mechanical stress from…